Sorafenib: A glimmer of hope for unresectable hepatocellular carcinoma?

Hepatology

Volumn 49, Issue 1, 2009, Pages 332-334

  Scanga, Andrew ^a   Kowdley, Kris ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VIRGINIA MASON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; DOXORUBICIN; MAPATUMUMAB; PLACEBO; SORAFENIB; SUNITINIB; TAMOXIFEN; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ADJUVANT THERAPY; ADVANCED CANCER; ANGIOGENESIS; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; HAND FOOT SYNDROME; HUMAN; HYPOPHOSPHATEMIA; LIVER CELL CARCINOMA; NONHUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RADIODIAGNOSIS; SHORT SURVEY; SIDE EFFECT; SURVIVAL TIME; SYSTEMIC THERAPY; TREATMENT DURATION; TUMOR VOLUME; WEIGHT REDUCTION;

EID: 61449191905     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22756     Document Type: Short Survey

References (16)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001; 2:533.
2. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008;48:S20.
3. Thomas MB. Systemic therapy for hepatocellular carcinoma. Cancer J 2008;14:123.
4. Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: A systematic review of randomized controlled trials. Ann Oncol 1997;8:117.
5. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. HEPATOLOGY 2003;37:429-442.
6. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 2006;66:11851-11858.
7. Llovet JP, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359: 378-390.
8. Bruix J, Sherman M. Management of hepatocellular carcinoma. HEPATOLOGY 2005;42:1208-1236.
9. Hopfner M, Schuppan D, Scherubl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008;14:1-14.
10. Zhu AX. Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma. Cancer 2008;112:250-259.
11. Villanueva A, Newell P, Chiang DY, Friedman SL, Llovet JM. Genomics and signaling pathways in hepatocellular carcinoma. Semin Liver Dis 2007;27:55-76.
12. Chu D, Lacouture ME, Fillos T, Wu S. Risk of hand-foot skin reaction with sorafenib: A systematic review and meta-analysis. Acta Oncol 2008; 47:176-186.
13. Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J, et al. Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma [Abstract]. J Clin Oncol (Meeting Abstracts) 2008; 26(Suppl):4509.
14. Hotte SJ, Hirte HW, Chen EX, Siu LL, Le LH, Corey A, et al. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAILR1) in patients with advanced solid malignancies. Clin Cancer Res 2008; 14:3450-3455.
15. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 2008;26:2992-2998.
16. Thomas MB, Chadha R, Glover K, Wang X, Morris J, Brown T, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007;110:1059-1067.